

# Molecular diagnostics of respiratory pathogens

r-biopharm®



Reliable real-time PCR solution



## Practical:

Same workflow and same cycler profile for all RIDA®GENE products



## Reliable:

All controls (internal, positive, negative) are included in the kit



## Rapid:

Results in less than 2h

More information:




[https://r-biopharm.com/respi\\_EN](https://r-biopharm.com/respi_EN)

# Information on our product portfolio

## Detection of respiratory pathogens

### Benefits



#### High analytical sensitivity

Device detection limit

- RNA assay > 50 copies/reaction
- DNA assay > 10 copies/reaction \*



#### High analytical specificity

- Verification of potentially interfering substances
- Verification of cross-reactivity



#### Quality

Development and manufacturing in Germany under ISO 13485


\* Exception: CAP Bac > 50 copies/reaction

### Parameters



#### Viruses

- SARS-CoV-2
- Influenza (A/B)
- H1N1v
- RSV
- Adenovirus
- Parainfluenza (1/2/3/4)
- hMPV



#### Bacteria

- *Bordetella pertussis*
- *Bordetella holmesii*
- *Bordetella parapertussis*
- *Chlamydomphila pneumoniae*
- *Mycoplasma pneumoniae*
- *Legionella pneumophila*



#### Fungi

- *Pneumocystis jirovecii*

### Diagnostics of respiratory pathogens

Respiratory infections are widespread and are caused by a broad spectrum of pathogens. To control the spread of these mostly highly infectious pathogens, rapid diagnosis is essential. The RIDA®GENE tests offer a reliable and efficient way to detect a broad spectrum of respiratory pathogens, such as viruses, bacteria and fungi, in less than 2 hours.



Reliable and rapid identification of the pathogen using the RIDA®GENE tests is essential for both appropriate patient treatment and prevention of further pathogen transmission.



## Respiratory infections

**Influenza**, is a contagious respiratory infectious disease caused in humans by influenza A and influenza B viruses<sup>(1)</sup>. The disease symptoms of **SARS-CoV-2 & Influenza** virus infections are quite similar, including fever, cough & cold. SARS-Co-2 infections can vary widely in symptomatology and severity (asymptomatic to severe pneumonia with respiratory failure and death)<sup>(2, 3)</sup>.

**RSV, hMPV and Influenza** are the most predominant viral pathogens during the winter season, according to studies<sup>(4)</sup>.

**RSV** is associated with significant morbidity and mortality not only in children but also in elderly people, patients with preexisting conditions, and immunocompromised adults<sup>(5,6,7)</sup>.

**hMPV** infections can occur all year, but peaks of infection at the end of the winter season are common. Coinfections with other respiratory pathogens, e.g. RSV, have already been described several times<sup>(5,6,7)</sup>.

**Parainfluenza viruses (HPIV)** can also cause a variety of respiratory diseases. The clinical picture differs among types: HPIV-1 and -2 commonly cause croup and cold-like symptoms, while HPIV-3 is often associated with pneumonia and bronchiolitis. HPIV-4 is less well characterized to date, but is assumed to have a similar clinical picture to HPIV-3<sup>(8)</sup>.

***Pneumocystis jirovecii*** is an opportunistic pathogen that occurs in the human lung and causes *Pneumocystis jirovecii* pneumonia (PJP)<sup>(9)</sup>.

Opportunistic infections are a major problem in immunocompromised patients (e.g. due to HIV/AIDS, cancer, etc.) as their body cannot fight infections well. PJP causes symptoms including fever, cough, shortness of breath, chest pain, chills and exhaustion.

**Community-acquired pneumonia (CAP)** is the most frequently recorded infectious disease worldwide and leads to death in Western nations. Bacteria are the most common causative agents of CAP, and a distinction is drawn between typical and atypical pathogens<sup>(10)</sup>. Atypical CAP bacteria are difficult to detect. The most frequent atypical CAP bacteria include *Mycoplasma pneumoniae*, *Legionella* spp. and *Chlamydomphila pneumoniae*<sup>(11)</sup>.

***Bordetella pertussis*, *Bordetella parapertussis* and *Bordetella holmesii*** cause respiratory diseases. The clinical course of a *Bordetella* infection proceeds through three stages. Symptoms include cold, cough, and low-grade fever<sup>(12,13)</sup>. ***B. pertussis*** is the main causative agent of whooping cough<sup>(13)</sup>. Less frequently, infections with *B. parapertussis* or *B. holmesii* can also lead to a clinical picture similar to whooping cough. However, the course of this disease is usually milder and shorter than in the case of disease caused by *B. pertussis*.

## Ordering information

Product	Matrix	Analyt (Target)	Art. No.
RIDA®GENE Flu	Nasal-/throat swabs	Influenza A (M protein gene), Influenza B (NP gene), H1N1v (H1 gene)	PG0505
RIDA®GENE Flu & SARS-CoV-2	Nasal-/throat swabs	Influenza A (M gene), Influenza B (NP1 gene), SARS-CoV-2 (E gene; RdRp gene)	PG6825
RIDA®GENE Flu & RSV	Nasal-/throat swabs; BAL	Influenza A (M protein gene), Influenza B (NP1 gene), RSV (F gene)	PG0545
RIDA®GENE RSV & hMPV	Nasal-/throat swabs	RSV A/B = F-Gen, hMPV A/B = F-Glycoprotein	PG5905
RIDA®GENE Parainfluenza	Nasal-/throat swabs; BAL	Parainfluenza 1, Parainfluenza 3, Parainfluenza 2/4 (HN gene)	PG5805
RIDA®GENE Adenovirus	Nasopharyngeal swabs	Adenovirus (Hexon)	PG1005
RIDA®GENE Bordetella	BAL	<i>B. pertussis</i> (IS481), <i>B. parapertussis</i> (pIS1001), <i>B. holmesii</i> (IS481, hIS1001)	PG2505
RIDA®GENE CAP Bac	BAL	<i>Cp. pneumoniae</i> (16S rRNA), <i>L. pneumophila</i> (16S rRNA), <i>M. pneumonia</i> (IGS)	PG2705
RIDA®GENE Pneumocystis jirovecii	Nasal-/throat swabs	<i>P. jirovecii</i> (mt LSU; large subunit)	PG1905

- Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC, et al. Influenza. Nat Rev Dis Primers. 2018;4(1):3.
- Institut RK. Epidemiologischer Steckbrief zu SARS-CoV-2 und COVID-19 2021 [25.10.2021]. Available from: [https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\\_Coronavirus/Steckbrief.html](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Steckbrief.html).
- Institut RK. Influenza 2021 [25.10.2021]. Available from: [https://www.rki.de/DE/Content/InfAZ/I/Influenza/IPV/Influenza.html?cms\\_current=Influenza&cms\\_lv2=2961756&cms\\_box=1](https://www.rki.de/DE/Content/InfAZ/I/Influenza/IPV/Influenza.html?cms_current=Influenza&cms_lv2=2961756&cms_box=1)
- Al-Romaihi HE, Smatti MK, Ganesan N, Nadeem S, Farag E, Coyle PV, Nader, JD, Al-Khatib HA, Elmagboul EB, Al Dhahry S, Al-Marri SA, Al Thani AA, Al Khal A, Al Maslamani MA, Yassine HM. Epidemiology of respiratory infections among adults in Qatar (2012-2017). PloS One. 2019; 14(6): e0218097.
- Luo H-J, Huang X-B, Zhong H-L, Ye C-X, Tan X, Zhou K, Yuan L, Zhang S-F, Zhu X, Lin C-J, Wang W-J, Xu L, Cao K-Y. Epidemiological characteristics and phylogenetic analysis of human respiratory syncytial virus in patients with respiratory infections during 2011-2016 in southern China. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases. 2020; 90: 5–17.
- Vieira SE, Thomazelli LM, de Paulis M, Ferronato AE, Oliveira DB, Martinez MB, Durigon EL. Infections Caused by HRSV A ON1 Are Predominant among Hospitalized Infants with Bronchiolitis in São Paulo City. BioMed Research International.2017; 3459785
- Rodriguez PE, Frutos MC, Adamo MP, Cuffini C, Cámara JA, Paglini MG, Moreno L, Cámara A. Human Metapneumovirus: Epidemiology and genotype diversity in children and adult patients with respiratory infection in Córdoba, Argentina. PloS One. 2020; 15(12): e0244093.
- DeGroot NP, Haynes AK, Taylor C, Killerby ME, Dahl RM, Mustaqim D, et al. Human parainfluenza virus circulation, United States, 2011-2019. J Clin Virol. 2020;124:104261.
- Sokulska M, Kicia M, Wesolowska M, Piesiak P, Kowal A, Lobo ML, et al. Genotyping of Pneumocystis jirovecii in colonized patients with various pulmonary diseases. Med Mycol. 2018;56(7):809-15.
- Höffken G, Lorenz J, Kern W, Welte T, Bauer T, Dalhoff K, Dietrich E, Ewig S, Gastmeier P, Grabein B, Halle E, Kolditz M, Marre R, Sitter H. [Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany]. Pneumologie. 2009; 63:e1-68.
- Ramirez JA, Anzueto AR. Changing needs of community-acquired pneumonia. Journal of Antimicrobial Chemotherapy. 2011; 66 Suppl 3:iii3-9.
- Chow SK, Arbefeville S, Boyanton BL, Jr., Dault EM, Dunn J, Ferrieri P, et al. Multicenter Performance Evaluation of the Simplexa Bordetella Direct Kit in Nasopharyngeal Swab Specimens. J Clin Microbiol. 2020;59(1).
- Institut RK. Keuchhusten (Pertussis) 2020 [Available from: [https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber\\_Pertussis.html](https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Pertussis.html)].